FDA staff review raises questions about MannKind diabetes device

[riky]

FDA staff review raises questions about MannKind diabetes device

<p><a href="http://news.yahoo.com/fda-staff-review-raises-questions-mannkind-diabetes-device-130152756--sector.html"><img src="http://l1.yimg.com/bt/api/res/1.2/ZnKXdair_oAoSt9Sr6uzpg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-03-28T130152Z_1_CBREA2R107900_RTROPTP_2_CHINA-PHARMACEUTICALS.JPG" width="130" height="86" alt="A view shows the U.S. Food and Drug Administration (FDA) logo at its headquarters in Silver Spring" align="left" title="A view shows the U.S. Food and Drug Administration (FDA) logo at its headquarters in Silver Spring" border="0" /></a>By Toni Clarke WASHINGTON (Reuters) - A review of MannKind Corp's experimental inhaled insulin device by U.S. Food and Drug Administration staff raised questions about its safety and effectiveness but was less damning than some investors had expected. The company's shares initially rose as much as 10.6 percent before falling back amid conflicting opinions from analysts on how the FDA will likely rule. The reviewers issued their report ahead of a meeting on Tuesday of outside advisers to the FDA, who will discuss clinical trial data and advise on whether the product, Afrezza, should be approved. The FDA is not obliged to follow the advice of its advisory panels but typically does so.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login